https://www.biospace.com/employer/401314/regenxbio REGENXBIO en-US Wed, 23 Jun 2021 15:02:16 GMT https://www.biospace.com/dutch-biotech-acquires-corlieve-to-develop-treatment-for-temporal-lobe-epilepsy Vanessa Doctor, RN uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter's lead program, AMT-260, an advanced treatment for TLE. Wed, 23 Jun 2021 15:02:16 GMT https://www.biospace.com/dutch-biotech-acquires-corlieve-to-develop-treatment-for-temporal-lobe-epilepsy https://www.biospace.com/collaboration-is-key-for-rare-disease-fda-nih-10-pharmas-and-5-nonprofits-form-consortium Kate Goodwin Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease. Thu, 28 Oct 2021 13:17:56 GMT https://www.biospace.com/collaboration-is-key-for-rare-disease-fda-nih-10-pharmas-and-5-nonprofits-form-consortium https://www.biospace.com/biospace-movers-and-shakers-sept-10 Alex Keown Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. Thu, 09 Sep 2021 15:49:25 GMT https://www.biospace.com/biospace-movers-and-shakers-sept-10 https://www.biospace.com/potential-mps-1-therapy-shows-biomarker-activity-improved-function Hayley Shasteen REGENXBIO presented results from its ongoing Phase I/II trial of RGX-111, an investigational one-time gene therapy for people with Mucopolysaccharidosis Type I (MPS I). Wed, 09 Feb 2022 21:39:02 GMT https://www.biospace.com/potential-mps-1-therapy-shows-biomarker-activity-improved-function https://www.biospace.com/regenxbio-enjoys-week-of-gene-therapy-successes-in-diabetic-retinopathy-and-mps Hannah Chudleigh Six months after the one-time treatment, 47% of patients in Cohort 1 demonstrated a promising two-step or greater improvement in their diabetic retinopathy. Mon, 14 Feb 2022 19:42:00 GMT https://www.biospace.com/regenxbio-enjoys-week-of-gene-therapy-successes-in-diabetic-retinopathy-and-mps https://www.biospace.com/companies-look-to-fly-high-like-bluebird-with-new-gene-therapies Mark Terry BioSpace looks at several companies developing new gene therapies in the wake of the FDA recommending two of bluebird bio’s lentiviral vector gene therapies. Mon, 13 Jun 2022 15:58:54 GMT https://www.biospace.com/companies-look-to-fly-high-like-bluebird-with-new-gene-therapies https://www.biospace.com/bluebird-spreads-wings-after-company-split-with-priority-review-for-gene-therapy Kate Goodwin The FDA has granted Cambridge-based bluebird Bio a Priority Review of its Biologics License Application for betibeglogene autotemcel (beti-cel). Mon, 22 Nov 2021 15:38:23 GMT https://www.biospace.com/bluebird-spreads-wings-after-company-split-with-priority-review-for-gene-therapy https://www.biospace.com/aao-2022-janssen-regenxbio-apellis-and-more Tristan Manalac Gene therapies developed by Janssen, Atsena, REGENXBIO and AbbVie showed promise against eye diseases this weekend at the American Academy of Ophthalmology 2022 meeting. Mon, 03 Oct 2022 14:11:28 GMT https://www.biospace.com/aao-2022-janssen-regenxbio-apellis-and-more https://www.biospace.com/clinical-catch-up-august-3-7 Mark Terry It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. Thu, 06 Aug 2020 14:53:51 GMT https://www.biospace.com/clinical-catch-up-august-3-7 https://www.biospace.com/how-covid-19-is-catalyzing-a-better-more-efficient-biopharma-environment Gail Dutton The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October. Wed, 04 Nov 2020 13:31:12 GMT https://www.biospace.com/how-covid-19-is-catalyzing-a-better-more-efficient-biopharma-environment